Company Overview of Prexton Therapeutics SA
Prexton Therapeutics SA develops Parkinson’s drugs that target the metabotropic glutamate receptors mGluR3 and mGluR4. The company was founded in 2012 and is based in Geneva, Switzerland.
Chemin des Aulx 14
Founded in 2012
Key Executives for Prexton Therapeutics SA
Prexton Therapeutics SA Key Developments
Similar Private Companies By Industry
|Acino International AG||Europe|
|Albea Pharmaceuticals AG||Europe|
|Alpen Pharma AG||Europe|
|Alpex Pharma SA||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Prexton Therapeutics SA, please visit www.prextontherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.